Standard Article

Platinum-Based Anticancer Drugs

  1. Marc S. Robillard,
  2. Jan Reedijk

Published Online: 15 MAR 2006

DOI: 10.1002/0470862106.ia193

Encyclopedia of Inorganic Chemistry

Encyclopedia of Inorganic Chemistry

How to Cite

Robillard, M. S. and Reedijk, J. 2006. Platinum-Based Anticancer Drugs . Encyclopedia of Inorganic Chemistry.

Author Information

  1. Leiden University, Leiden, The Netherlands

Publication History

  1. Published Online: 15 MAR 2006

Abstract

The chemotherapeutic agent cisplatin enjoys the status of one of the world's best-selling anticancer drugs. As is the case with other chemotherapeutic drugs, however, cisplatin has its drawbacks, including intrinsic or acquired resistance and toxicity. Efforts to mitigate cisplatin's drawbacks have inspired the synthesis of myriad analogs, but with only a handful that have been shown to be acceptable for clinical application. Increased understanding of the mechanism of the action of cisplatin, as a result of decades of research, is leading to a more rational design of new platinum drugs. However, the incomplete puzzle of cisplatin's ways and the lack of a single decisive biological target for anticancer treatment still complicate the search for improved platinum drugs. This article gives a brief introduction to cisplatin, and subsequently summarizes and evaluates the development of cisplatin derivatives and possible new approaches.

Keywords:

  • platinum;
  • cisplatin;
  • cancer;
  • drugs;
  • DNA;
  • proteins;
  • toxicity;
  • resistance;
  • targeting;
  • combinatorial